SCHEMBL7933259

SCHEMBL7933259

CSc1cnc(C(=O)Nc2ccnc(CNc3cccnc3N)c2)cn1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.56
PRKCI P41743 4/20 0.43
HDAC1 Q13547 2/20 0.38
HDAC3 O15379 1/20 0.38
NCOR1 O75376 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GRM4 Q14833 1/20 0.38
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
VCP P55072 1/20 0.36
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7939629 0.91 BACE1 (0.54) BACE1PRKCIHDAC1HDAC3NCOR1
SCHEMBL7944708 0.88 BACE1 (0.52) BACE1PRKCISMN1; SMN2NPC1RAB9A
SCHEMBL7942253 0.87 BACE1 (0.58) BACE1PRKCISMN1; SMN2NPC1RAB9A
SCHEMBL7942380 0.87 BACE1 (0.74) BACE1HDAC1HDAC3NCOR1HDAC2
SCHEMBL7943507 0.86 BACE1 (0.57) BACE1PRKCIHDAC1HDAC3NCOR1
SCHEMBL7940587 0.85 BACE1 (0.77) BACE1PRKCI
SCHEMBL7945376 0.84 BACE1 (0.54) BACE1SMN1; SMN2NPC1RAB9A
SCHEMBL7932754 0.84 BACE1 (0.55) BACE1PRKCIHDAC1HDAC3HDAC2
SCHEMBL7942788 0.84 BACE1 (0.65) BACE1PRKCI
SCHEMBL7944982 0.84 BACE1 (0.64) BACE1PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885PRKCI 2747/4885HDAC1 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.